Palvella Therapeutics (PVLA) Common Equity (2016 - 2024)
Historic Common Equity for Palvella Therapeutics (PVLA) over the last 12 years, with Q3 2024 value amounting to -$87.4 million.
- Palvella Therapeutics' Common Equity fell 38647.66% to -$87.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$87.4 million, marking a year-over-year decrease of 38647.66%. This contributed to the annual value of -$74.5 million for FY2023, which is 36668.7% down from last year.
- According to the latest figures from Q3 2024, Palvella Therapeutics' Common Equity is -$87.4 million, which was down 38647.66% from -$80.8 million recorded in Q2 2024.
- Palvella Therapeutics' 5-year Common Equity high stood at $53.9 million for Q3 2021, and its period low was -$87.4 million during Q3 2024.
- In the last 5 years, Palvella Therapeutics' Common Equity had a median value of $38.2 million in 2021 and averaged $15.2 million.
- In the last 5 years, Palvella Therapeutics' Common Equity skyrocketed by 13952.78% in 2020 and then tumbled by 59730.24% in 2024.
- Over the past 5 years, Palvella Therapeutics' Common Equity (Quarter) stood at $31.0 million in 2020, then surged by 63.58% to $50.8 million in 2021, then plummeted by 44.97% to $27.9 million in 2022, then tumbled by 366.69% to -$74.5 million in 2023, then fell by 17.35% to -$87.4 million in 2024.
- Its last three reported values are -$87.4 million in Q3 2024, -$80.8 million for Q2 2024, and -$76.9 million during Q1 2024.